Cover Image
市場調查報告書

基質金屬蛋白酶 9 (明膠酶 B/92kDa-4型膠原酵素/92 kDa 明膠酶/MMP9/EC 3.4.24.35) :開發平台分析

Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 363574
出版日期 內容資訊 英文 57 Pages
訂單完成後即時交付
價格
Back to Top
基質金屬蛋白酶 9 (明膠酶 B/92kDa-4型膠原酵素/92 kDa 明膠酶/MMP9/EC 3.4.24.35) :開發平台分析 Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Pipeline Review, H2 2016
出版日期: 2016年10月26日 內容資訊: 英文 57 Pages
簡介

基質金屬蛋白酶 9 (MMP-9) 是屬於鋅金屬蛋白酶家族的一員,在細胞外基質的局部的蛋白質分解,白血球移動及骨製骨破壞性融噬發揮重要作用。與彈性蛋白酶一起的MMP9,是底膜中的好中性移動的調整要素。MMP9,在創傷修復,血管新生及新血管新生擔任重要的工作。

本報告提供的基質金屬蛋白酶 9 (明膠酶 B/92kDa-4型膠原酵素/92 kDa 明膠酶/MMP9/EC 3.4.24.35的)抑制劑開發平台的現狀及最新更新的各開發階段比較分析,企業和研究機關開發中的治療藥,治療藥的評估,後期階段及中止的計劃相關資訊等最新的新聞和發表。

簡介

  • 調查範圍

基質金屬蛋白酶 9 (明膠酶 B/92kDa-4型膠原酵素/92 kDa 明膠酶/MMP9/EC 3.4.24.35) :概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/研究機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Calypso Biotech SA
  • Gilead Sciences, Inc.
  • Shulov Innovative Science Ltd.

藥物簡介

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0613TDB

Summary

Global Markets Direct's, 'Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Pipeline Review, H2 2016', provides in depth analysis on Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted pipeline therapeutics.

The report provides comprehensive information on the Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35)
  • The report reviews Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents 2
  • List of Tables 5
  • List of Figures 5
  • Introduction 6
  • Global Markets Direct Report Coverage 6
  • Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) Overview 7
  • Therapeutics Development 8
  • Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Products under Development by Stage of Development 8
  • Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Products under Development by Therapy Area 9
  • Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Products under Development by Indication 10
  • Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Pipeline Products Glance 12
  • Late Stage Products 12
  • Early Stage Products 13
  • Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Products under Development by Companies 14
  • Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Products under Development by Universities/Institutes 17
  • Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Therapeutics Assessment 19
  • Assessment by Monotherapy/Combination Products 19
  • Assessment by Mechanism of Action 20
  • Assessment by Route of Administration 21
  • Assessment by Molecule Type 23
  • Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Companies Involved in Therapeutics Development 25
  • Calypso Biotech SA 25
  • Gilead Sciences, Inc. 26
  • Iproteos S.L. 27
  • Shulov Innovative Science Ltd. 28
  • Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Drug Profiles 29
  • AQU-005 - Drug Profile 29
  • Product Description 29
  • Mechanism Of Action 29
  • R&D Progress 29
  • AQU-010 - Drug Profile 30
  • Product Description 30
  • Mechanism Of Action 30
  • R&D Progress 30
  • AQU-118 - Drug Profile 31
  • Product Description 31
  • Mechanism Of Action 31
  • R&D Progress 31
  • CALY-001 - Drug Profile 32
  • Product Description 32
  • Mechanism Of Action 32
  • R&D Progress 32
  • GS-5745 - Drug Profile 33
  • Product Description 33
  • Mechanism Of Action 33
  • R&D Progress 33
  • IPRO-003 - Drug Profile 35
  • Product Description 35
  • Mechanism Of Action 35
  • R&D Progress 35
  • Monoclonal Antibodies to Inhibit MMP-2 and MMP-9 for Immunology and Gastrointestinal Disorders - Drug Profile 36
  • Product Description 36
  • Mechanism Of Action 36
  • R&D Progress 36
  • ND-336 - Drug Profile 37
  • Product Description 37
  • Mechanism Of Action 37
  • R&D Progress 37
  • ND-478 - Drug Profile 38
  • Product Description 38
  • Mechanism Of Action 38
  • R&D Progress 38
  • Recombinant MMP-9 Replacement for Liver Fibrosis, Pulmonary Fibrosis, Dupuytren Contracture, Peyronies Disease and Islet Transplantation - Drug Profile 39
  • Product Description 39
  • Mechanism Of Action 39
  • R&D Progress 39
  • Recombinant Protein to Target MMP-9 for Wounds - Drug Profile 40
  • Product Description 40
  • Mechanism Of Action 40
  • R&D Progress 40
  • SI-1004 - Drug Profile 41
  • Product Description 41
  • Mechanism Of Action 41
  • R&D Progress 41
  • SI-1005 - Drug Profile 42
  • Product Description 42
  • Mechanism Of Action 42
  • R&D Progress 42
  • Small Molecule to Inhibit Matrix Metalloproteinase 9 for Oncology - Drug Profile 43
  • Product Description 43
  • Mechanism Of Action 43
  • R&D Progress 43
  • Small Molecules to Inhibit Carbonic Anhydrases and MMPs for Metastatic Melanoma - Drug Profile 44
  • Product Description 44
  • Mechanism Of Action 44
  • R&D Progress 44
  • Small Molecules to Inhibit MMP for Myocardial Infarction - Drug Profile 45
  • Product Description 45
  • Mechanism Of Action 45
  • R&D Progress 45
  • ZEP-3 - Drug Profile 46
  • Product Description 46
  • Mechanism Of Action 46
  • R&D Progress 46
  • Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Dormant Projects 47
  • Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Discontinued Products 51
  • Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Featured News & Press Releases 52
  • Sep 21, 2016: Gilead Terminates Phase 2/3 Study of GS-5745 in Patients With Ulcerative Colitis 52
  • Jun 28, 2016: NeuroMax Announces Start Phase 1 Clinical Trial of AQU-005 for the Treatment of Neuropathic Pain 52
  • May 13, 2015: Abzena provides an update on the clinical development of one of the humanized antibodies created using its Composite Human Antibody technology 52
  • Dec 26, 2011: New Antibodies Treat Autoimmune Disease in Mice 53
  • Oct 08, 2011: Researchers from Notre Dame university create breakthrough in neurological diseases 54
  • Oct 06, 2011: Notre Dame researchers make neurological disease breakthrough 55
  • Appendix 56
  • Methodology 56
  • Coverage 56
  • Secondary Research 56
  • Primary Research 56
  • Expert Panel Validation 56
  • Contact Us 56
  • Disclaimer 57

List of Tables

  • Number of Products under Development for, H2 2016 8
  • Number of Products under Development by Therapy Area, H2 2016 9
  • Number of Products under Development by Indication, H2 2016 10
  • Comparative Analysis by Late Stage Development, H2 2016 12
  • Comparative Analysis by Early Stage Products, H2 2016 13
  • Number of Products under Development by Companies, H2 2016 14
  • Products under Development by Companies, H2 2016 15
  • Products under Development by Companies, H2 2016 (Contd..1) 16
  • Number of Products under Investigation by Universities/Institutes, H2 2016 17
  • Products under Investigation by Universities/Institutes, H2 2016 18
  • Assessment by Monotherapy/Combination Products, H2 2016 19
  • Number of Products by Stage and Mechanism of Action, H2 2016 20
  • Number of Products by Stage and Route of Administration, H2 2016 22
  • Number of Products by Stage and Molecule Type, H2 2016 24
  • Pipeline by Calypso Biotech SA, H2 2016 25
  • Pipeline by Gilead Sciences, Inc., H2 2016 26
  • Pipeline by Iproteos S.L., H2 2016 27
  • Pipeline by Shulov Innovative Science Ltd., H2 2016 28
  • Dormant Projects, H2 2016 47
  • Dormant Projects (Contd..1), H2 2016 48
  • Dormant Projects (Contd..2), H2 2016 49
  • Dormant Projects (Contd..3), H2 2016 50
  • Discontinued Products, H2 2016 51

List of Figures

  • Number of Products under Development for, H2 2016 8
  • Number of Products under Development by Therapy Area, H2 2016 9
  • Number of Products under Development by Top 10 Indication, H2 2016 10
  • Comparative Analysis by Late Stage Development, H2 2016 12
  • Comparative Analysis by Early Stage Products, H2 2016 13
  • Assessment by Monotherapy/Combination Products, H2 2016 19
  • Number of Products by Stage and Mechanism of Actions, H2 2016 20
  • Number of Products by Routes of Administration, H2 2016 21
  • Number of Products by Stage and Routes of Administration, H2 2016 21
  • Number of Products by Molecule Types, H2 2016 23
  • Number of Products by Stage and Molecule Type, H2 2016 23
Back to Top